FDA Minds DTC “Reminder Ad” Increase, Seeks Better “Brief Summaries”
This article was originally published in The Tan Sheet
Executive Summary
FDA is concerned that industry may be using "reminder ads" more frequently as a way to avoid including risk information in direct-to-consumer marketing
You may also be interested in...
DTC Ad Endorsement Policy Should Be Consistent With OTC Practice – FTC
Endorsements and testimonials in direct-to-consumer advertising for prescription drugs should be subject to the same standards the Federal Trade Commission applies to OTC drug ads, FTC advises in Dec. 1 comments to the agency
DTC Ad Endorsement Policy Should Be Consistent With OTC Practice – FTC
Endorsements and testimonials in direct-to-consumer advertising for prescription drugs should be subject to the same standards the Federal Trade Commission applies to OTC drug ads, FTC advises in Dec. 1 comments to the agency
DTC Ad Endorsement Policy Should Be Consistent With OTC Practice – FTC
Endorsements and testimonials in direct-to-consumer advertising for prescription drugs should be subject to the same standards the Federal Trade Commission applies to OTC drug ads, FTC advises in Dec. 1 comments to the agency